Recently, immune checkpoint-blocking agents, which target PD-1/PD-L1 pathways in T cells to enhance anti-tumor immune responses, have shown promising anti-tumor activity and provided a new paradigm in cancer therapy [1, 2]. The gene discussed is CD274; the disease is neoplasm.